ratiopharm Group
Division of Teva Pharmaceutical Industries Ltd.
www1.ratiopharm.com
Latest From ratiopharm Group
Ranitidine Recalls Begin As European Regulators Take Action
OTC ranitidine products are among the first to be recalled in Europe following the discovery of a human carcinogen in ranitidine-based drugs.With investigations underway worldwide, regulators across Europe are split into two camps: immediate action or wait and see.
Generics Players Dominating New OTC Launches In Germany
An analysis by Sempora Consulting of the German OTC market in 2018 shows that generic products dominate new OTC product launches.
Generics Players Dominating New OTC Launches In Germany
An analysis by Sempora Consulting of the German OTC market in 2018 shows that generic products dominate new OTC product launches.
Germany Approves Trilogy Of Switches
Three prescription-to-OTC switches approved in Germany: Levocetirizine for oral use, diclofenac for use as a patch, and preparations containing sodium bituminosulfonate and hydrocortisone acetate.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Therapeutic Areas
- Non-Specific
- Alias(es)
- ratiopharm GMBH
- Magnafarma
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Germany
-
Germany
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
- Oliver Windholtz, CEO
- Contact Info
-
ratiopharm Group
Phone: (49) 731 402 02
Graf-Arco-Strasse 3
P.O. Box 3380 Ulm, 89079
Germany
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ratiopharm Group
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice